Biocytogen to Present Progress of Antibody Assets and Five Fully Human Antibody Discovery Platforms at ChinaBio 2022

Biocytogen to Present Progress of Antibody Assets and Five Fully Human Antibody Discovery Platforms at ChinaBio 2022

Biocytogen’s BD & Licensing team will attend and present at the upcoming ChinaBio virtual conference on November 8-11, 2022.

The company will give an oral presentation with the title of “Introduction of Biocytogen’s pipeline assets, innovative fully human antibody RenMice platform and Project Integrum for antibody discovery against 1000+ potential targets”. The talk will introduce Biocytogen’s clinical asset YH003 (CD40 antibody) and preclinical assets YH008 (PD-1×CD40 BsAb), YH006 (CTLA-4×OX40 fully human BsAb) and YH013 (EGFR×MET BsADC). The talk will also highlight the latest progress of Project Integrum and introduce the company’s five proprietary RenMiceTM-based fully human antibody discovery platforms, which are designed to facilitate the discovery of monoclonal antibodies, bispecific antibodies, bispecific ADCs, TCR-mimic antibodies and antibodies targeting GPCRs. In addition, the company’s flexible business collaboration models and collaboration progress will be introduced.

Biocytogen’s attendees will also host one-on-one partnering meetings. Our experts look forward to discussing licensing and co-development opportunities with you. 

For questions, please contact us at [email protected].

To reserve a one-on-one meeting with us via PartneringONE, click here.

Log in to watch the presentation (only in English), click here.

About Biocytogen

Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit


Back to top